NVN. V. Varekha

N. V. Varekha

*This is an algorithmically generated author record based on publicly available information.

N. V. Varekha has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a method for differential diagnosis of iron deficiency anemia and anemia of chronic disease based on demographic data and routine laboratory tests using machine learning technologies

    by N. V. Varekha, N. I. Stuklov, K. V. Gordienko, R. R. Gimadiev, O. B. Shchegolev, S. N. Kislaya, E. V. Gubina, A. A. Gurkina

    Background. The study of machine learning methods, a branch of artificial intelligence science, is relevant for the development of optimal screening strategies, identification of risk groups, and application of less expensive and more accessible laboratory tests to assess the body iron status. Aim. To select an appropriate artificial intelligence algorithm for predicting serum ferritin (SF) levels and to evaluate its applicability for differential diagnosis of iron deficiency anemia and anemia of chronic diseases. Materials and methods. A dataset of 9771 patients with micro‑normocytic anemia was used to create the model. On the basis of demographic data (gender and age), clinical blood count, C‑reactive protein level and known SF level, a regression model was developed to calculate the expected SF concentration in a particular patient and, using the same parameters, a classification model to determine the SF level group to which the patient belongs: I – 15 μg / L; II – 15–100 μg / L; III – 100–300 μg / L; Iv – ≥ 300 μg / L. Results. As a result, the regression model has moderate predictive ability (R2 = 0.70; median absolute error was 10.7 μg / L), the correlation coefficient between known and predicted SF level was r = 0.854 (p 0.05). The obtained classification model has high diagnostic accuracy for different clinical groups according to the SF level (AuC ROC was 0.91; 0.79; 0.84; 0.90 and 0.96; 0.76; 0.71; 0.82 for patients with reduced hemoglobin levels in women ( 120 g / L) and men ( 130 g / L) in groups I, II, III, Iv, respectively). Conclusion. Prediction of SF level using the developed models can be used as an accurate and clinically relevant tool for differential diagnosis of iron deficiency anemia (predicted SF is decreased ( 100 μg / L), C‑reactive protein is normal) and anemia of chronic diseases (predicted SF is normal or increased (100 μg / L), C‑reactive protein is increased) in real medical practice.


  • Open Access

    Correction of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction

    by A. A. Gurkina, N. I. Stuklov, V. A. Kokorin, R. R. Gimadiev, N. V. Varekha

       Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism.   Material and methods. An uncontrolled study included 30 patients with CHFpEF NYHA class I-III and anaemia. Patients received "standard therapy" for CHF in combination with sucrosomial iron (60 mg/day orally) for three months. Treatment response was assessed via clinical blood test, iron metabolism parameters, inflammatory markers, and functional tests at baseline and three months post-treatment.   Results. Anaemia in CHFpEF corresponds to anaemia of chronic disease with elevated hepcidin content, 219 (149-553) ng/mL occurs with impaired absorption and metabolism of iron and the development of iron deficiency. Hemoglobin levelincreased from 115 (98-117) g/L to 120 (103-133) g/L, p = 0.01, red blood cell count increased from 3.6 (3.5-4.1) × 1012/L to 4 (3.7-5.3) × 1012/L, p = 0.05, and serum ferritin increased from 106 (40-181) μg/L to 117 (83-166) μg/L, p = 0.04. N-terminal natriuretic propeptide (NT-proBNP) level decreased from 374 (330-443) ng/mL to 236 (128-349) ng/mL, p = 0.004. After treatment, exercise tolerance exercise tolerance improved: 6-minute walk test distance increased from 343.1 ± 100 m to 397±73 m (p = 0.01). Quality of life (QoL) level increased and was determined by the clinical status assessment scale (CAS), p = 0.01 and by the Minnesota Health Failure Questionnaire (MHFLQ), p = 0.002.   Conclusion. Adding oral hepcidin- independent iron to standard HFpEF therapy in patients with CHFpEF and anaemia significantly increased hemoglobin and serum ferritin levels, exercise tolerance, and QoL scores while reducing NT-proBNP levels and NYHA functional class after three months.